Multi-Center Evaluation of Survival and Toxicities following Radioembolization: analysis of the RESiN Registry. Journal of vascular and interventional radiology : JVIR Frantz, S., Matsuoka, L., Vaheesan, K., Petroziello, M., Golzarian, J., Wang, E., Gandhi, R., Collins, Z., Brower, J., Rachakonda, V. M., Du, L., Kennedy, A. S., Sze, D. Y., Lee, J., Brown, D. B. 2021


PURPOSE: To determine overall survival (OS), progression-free survival (PFS) and toxicity in a multicenter, real-world data collection using transarterial radioembolization (TARE) with resin microspheres.MATERIALS AND METHODS: 448 patents were treated at 36 centers between 2015-2019. Treatment history, baseline laboratory and imaging, and treatment goal were assessed. OS and PFS were stratified using Barcelona Clinic Liver Cancer (BCLC) and Child Pugh (CP) stratification. Kaplan-Meier analyses compared OS and PFS with 95% confidence intervals. Transplants were tracked. Toxicities were assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5. Cox Proportional Hazard of baseline demographics assessed factors affecting survival.RESULTS: Prior chemoembolization and systemic therapy were used in 107 (26%) and 68 (16%) of patients. Sixty-six patients (19%) were BCLC A and 202, 51, and 26 were BCLC B/C/D. Median OS for BCLC A patients was not reached at 30 months. Median OS for BCLC B/C/D patients was 19.5, 13.6, and 11.5 months (p=0.0006). Median PFS for BCLC A/B/C/D patients was 19.8, 10.0, 6.3, and 5.9 months (p=0.003). Twenty patients underwent transplant representing 14/43 (33%) undergoing bridge and 6/28 (21%) downstaging therapy. Common Grade 3 toxicities were encephalopathy (11/448, 2.5%), hyperbilirubinemia (10/448, 2.2%) and ascites (9/448, 2.0%). Factors predicting longer survival included CP A (X2=4.2, p=0.04) and BCLC A (X2=5.2, p=0.02).CONCLUSION: In a frequently pretreated patient cohort with disease burden in 81% beyond Milan criteria, TARE with resin microspheres provided OS comparable to other studies in this multicenter review.

View details for DOI 10.1016/j.jvir.2021.03.535

View details for PubMedID 33812981